INBS vs PFE

Intelligent Bio Solutions Inc. (INBS) continues to be a high-risk, high-reward investment, with an increased score reflecting material progress in its core drug screening technology. The completion of initial FDA clinical studies and commencement of Phase 2 are significant de-risking events, advancing its proprietary fingerprint technology toward commercialization. This strengthens its long-term p...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...